Systemic sclerosis (SSc) is characterized by multiple clinical manifestations. Vasculopathy is a main disease hallmark and ranges in severity from an exacerbated Raynaud phenomenon to pulmonary arterial hypertension (PAH). The potential involvement of the immune system in SSc-associated vascular abnormalities is not clear. Here, we set out to study SSc-related immune parameters and determine whether and which peripheral T cell subsets associate with vascular severity in SSc patients. Peripheral blood and clinical data were collected from 30 SSc patients, 5 patients with idiopathic PAH and 15 age and sex-matched healthy donors (HD). In this cross-sectional cohort, SSc patients with PAH (n = 15) were matched for their age, sex and medication with SSc patients with no signs of PAH (n = 15). Lymphocyte subsets were quantified by multi-colour flow cytometry. SSc patients exhibited elevated percentages of T peripheral helper cells (Tph), CD4+GZMB+ T cells and decreased levels of Th1 cells compared with HD. Increased presence of both CD4+ and CD8+ exhausted-like (CD28−) T cells, characterized by raised cytokine and cytotoxic signature, was also observed in SSc compared with HD blood. Furthermore, IL-4 expressing CD4+CD8+ T cells were significantly increased in SSc peripheral blood. Interestingly, the presence of PAH in SSc was accompanied by a distinct T helper profile, characterized by raised percentages of Th17 and Tph cells. SSc patients with severe vasculopathy (presence of PAH) exhibited a distinct T cell profile, suggesting a potential role of auto-immune inflammation in SSc vascular complications.
14 March 2025 in Rheumatology Advances in Practice
Patients with systemic lupus erythematosus (SLE) have increased risk of developing atherosclerotic cardiovascular disease (ASCVD). This excessive risk starts to accumulate during the earliest stages of SLE. ASCVD in SLE is associated with an adverse outcome. SLE-enhanced atherogenesis is most likely the consequence of a complex interplay between traditional risk factors and chronic auto-immune inflammation. This underscores the importance of conscientious management of traditional risk factors as well as maintaining low SLE disease activity. Shared immune pathways in SLE and ASCVD can affect the vascular biology of the atherosclerotic process in patients with SLE. In this review, we will discuss how the ASCVD risk evolves during the SLE disease course, and we consider whether patients with SLE are prone to developing superficial erosion of atherosclerotic plaques. This is highly relevant as pilot studies in the general population suggest antithrombotic therapy without stenting could be the better therapeutic approach in patients with plaque erosion.
Sander I van Leuven, Amy S Major; Accelerated atherosclerosis in systemic lupus erythematosus: don’t forget the devil we know!, Rheumatology, , kead329, https:/
Sander I van Leuven, Raphäel Duivenvoorden; CAR T-Cell therapy in systemic lupus erythematosus and beyond: a brave new world?, Rheumatology, , keae108, https://
1 January 2023 in Rheumatology Advances in Practice
This editorial refers to ‘Cocaine-induced granulomatosis with polyangiitis—an under-recognized condition’, by Gill et al.https://doi.org/10.1093/rap/rkad027.
2 January 2026 in Rheumatology Advances in Practice
Objectives: To explore the implementation of cardiovascular risk management (CVRM) in Dutch RA patients from the perspective of rheumatologists and patients. Methods: An online survey was conducted among Dutch rheumatologists, rheumatology physician assistants (PAs) and RA patients. Healthcare providers completed a 37-item adapted version of the Determinants of Implementation Behavior Questionnaire to assess various aspects of CVRM implementation behaviour on a 7-point Likert scale. Simultaneously, a 13-item questionnaire was administered to RA patients to gather experiences related to CVRM. Data for both surveys were collected online between 23 September and 1 December 2024. Results: A total of 85 healthcare providers [93% rheumatologists, mean age 47.2 years (s.d. 8.8), 72% female] and 145 RA patients [mean age 58 years (s.d. 12.6), 89% female] completed the survey. Providers did not seem to lack (self-reported) knowledge on CVRM, yet significant implementation challenges were identified across several domains, including skills, professional roles and beliefs about capabilities. Time constraints, limited resources, insufficient financial support and the absence of local protocols were cited as major barriers. From the patient perspective, only 39% reported being informed about RA-related cardiovascular risks, mostly by rheumatologists. Rheumatologists frequently provided guidance on physical activity (21%), while general practitioners were more active in managing traditional cardiovascular risk factors, prescribing medications (23%) and offering self-management advice (16%). Conclusion: Our study highlights the main challenges in implementing CVRM in daily practice, indicating the need for the development of targeted strategies to overcome these barriers.